-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2023-506112-40-00
5
2018-09-26
R/R Multiple Myeloma
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2023-503469-49-00
5
2018-04-19
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2023-507329-40-00
6
2017-09-28
1. Follicular Lymphoma
2. Chronic Lymphocytic Leukemia
3. Waldenstrom
-
2023-509354-58-00
5
2017-07-14
Mantle Cell Lymphoma
-
2023-509359-15-00
5
2017-03-08
Relapsed or Refractory Chronic Lymphocytic Leukemia
-
2023-505246-26-00
5
2016-01-27
High- or very-high risk, localized or locally advanced prostate cancer
-
2024-511348-25-00
10
2015-12-11
Myelodysplastic syndromes (MDS)
-
2024-518003-22-00
4
2023-01-20
Complicated urinary tract infections including acute pyelonephritis
-
2023-507865-24-00
5
2025-03-28
Advanced (unresectable/metastatic) melanoma
-
2024-510658-28-00
4
2024-09-24
Loss of renal function following cardiac surgery
-
2023-508736-62-00
4
2024-08-08
Heart failure (HF) with reduced ejection fraction (HFrEF)
-
2023-508737-13-00
4
2024-08-08
chronic heart failure
-
2023-508231-31-00
4
2024-07-24
Chronic Rhinosinusitis with Nasal Polyps
-
2022-502481-24-00
4
2024-05-23
Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)
-
2023-510127-30-00
1
2024-04-17
Relapsing Remitting Multiple Sclerosis (RRMS)
-
2022-502953-32-01
9
2024-04-02
Hereditary Angioedema (HAE)
-
2023-505396-71-00
4
2024-03-01
Early Alzheimer’s Disease with Biomarkers of Inflammation
-
2023-505292-73-00
4
2024-01-10
Alport syndrome